Chemokines and Their Receptors in Islet Allograft Rejection and as Targets for Tolerance Induction

• Main Authors: Shaheed Merani, Wayne W. Truong, Wayne Hancock, Colin C. Anderson, A. M. James Shapiro M.D., Ph.D.
• Format: Article
• Language: English
• Published: SAGE Publishing 2006-04-01
• Series: Cell Transplantation
• Online Access: https://doi.org/10.3727/000000006783981963
• ISSN: 0963-6897; 1555-3892

Graft rejection is a major barrier to successful outcome of transplantation surgery. Islet transplantation introduces insulin secreting tissue into type 1 diabetes mellitus recipients, relieving patients from exogenous insulin injection. However, insulitis of grafted tissue and allograft rejection prevent long-term insulin independence. Leukocyte trafficking is necessary for the launch of successful immune responses to pathogen or allograft. Chemokines, small chemotactic cytokines, direct the migration of leukocytes through their interaction with chemokine receptors found on cell surfaces of immune cells. Unique receptor expression of leukocytes, and the specificity of chemokine secretion during various states of immune response, suggest that the extracellular chemokine milieu specifically homes certain leukocyte subsets. Thus, only those leukocytes required for the current immune task are attracted to the inflammatory site. Chemokine blockade, using antagonists and monoclonal antibodies directed against chemokine receptors, is an emerging and specific immunosuppressive strategy. Importantly, chemokine blockade may potentiate tolerance induction regimens to be used following transplantation surgery, and prevent the need for life-long immunosuppression of islet transplant recipients. Here, the role for chemokine blockade in islet transplant rejection and tolerance is reviewed.